Mr. Marcos Agramont reports
ISODIOL INTERNATIONAL INC. ANNOUNCES UNAUDITED QUARTERLY PROFIT OF ISO INTERNATIONAL LLC
Isodiol International Inc. has released the operational numbers of its wholly owned subsidiary for the period from April 1, 2017, to June 30, 2017. ISO International LLC recorded unaudited fiscal Q1 profits of $897,596 based on revenues of $4,919,693.
Marcos Agramont, chief executive officer of Isodiol, stated: "Demonstrating Q1 profitability is a major milestone for our company and our investors. The cannabis industry on a whole will be legitimized by demonstrating successful commercialization and operating in an environment which promotes the cannabis movement. We have developed product lines and brands which will generate revenues and profitability and now we're positioned to begin exploring additional expansion opportunities. Vertical integration, expanding product distribution channels, and out-of-state manufacturing and processing are all opportunities we will aggressively develop and execute."
About Isodiol International Inc.
Isodiol International is the market leader in pharmaceutical grade cannabis compounds and the industry leader in manufacturing and development of consumer products. Isodiol's nutraceutical division is the pioneer of many firsts for hemp-derived cannabidiol (CBD), including 99-per-cent-pure crystalline isolate, microencapsulation and nanotechnology for the highest-quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, seeking joint ventures and acquisitions to expand its portfolio of brands and subsidiaries, and will aggressively continue international expansion into Latin America, Asia and Europe.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.